# First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

> **NCT01521715** · PHASE4 · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 44 (actual)

## Conditions studied

- Locally Advanced and/or Metastatic Renal Cell Carcinoma
- Carcinoma, Renal Cell
- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01521715
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-24
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-07-31
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01521715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01521715, "First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01521715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*